Pfizer (PFE)
21.59
-0.90 (-4.00%)
NYSE · Last Trade: Apr 11th, 1:16 AM EDT
Detailed Quote
Previous Close | 22.49 |
---|---|
Open | 22.26 |
Bid | 21.59 |
Ask | 21.64 |
Day's Range | 21.09 - 22.27 |
52 Week Range | 20.92 - 31.54 |
Volume | 72,960,886 |
Market Cap | 121.05B |
PE Ratio (TTM) | 15.31 |
EPS (TTM) | 1.4 |
Dividend & Yield | 1.680 (7.78%) |
1 Month Average Volume | 64,000,226 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.
Via Stocktwits · April 10, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Thursday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · April 10, 2025
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This added layer of uncertainty reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.
Via StockStory · April 10, 2025
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.
Via Investor's Business Daily · April 10, 2025
Rock-bottom prices don't always mean rock-bottom businesses.
The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?
Via StockStory · April 10, 2025
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.
Via Investor's Business Daily · April 10, 2025
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.
By Pfizer Inc. · Via Business Wire · April 10, 2025
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Via Benzinga · April 9, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · April 9, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · April 9, 2025
Pfizer Inc (NYSE:PFE) shares are moving lower Wednesday alongside several pharmaceutical giants after President Donald Trump indicated that tariffs on pharmaceutical companies are on the horizon.
Via Benzinga · April 9, 2025
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Via Investor's Business Daily · April 9, 2025
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.
Via Benzinga · April 9, 2025
Via The Motley Fool · April 9, 2025
Via The Motley Fool · April 9, 2025
SPONSORED CONTENT -- (StatePoint) Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you can take to reduce your risk of serious illness.
Via StatePoint Media · April 9, 2025
The Oracle of Omaha has proven his investing chops yet again.
Via Talk Markets · April 8, 2025
While the tariff situation has created a great deal of uncertainty and stock prices have crashed in tow, one silver lining is that dividend yields have at least ticked up.
Via Talk Markets · April 8, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · April 8, 2025
The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.
Via The Motley Fool · April 8, 2025
Stay informed about the most active stocks in the S&P500 index on Monday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · April 7, 2025
Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major sectors.
Via Benzinga · April 7, 2025
Try not to let market volatility bring you down. Instead, let dividend stocks make you happy. These high-yield dividend stocks will pay you between 3% and 7% to hold them.
Via The Motley Fool · April 5, 2025
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Via Benzinga · April 4, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · April 4, 2025